Clarivate Plc (CLVT) Stock Analysis and Metrics

Clarivate

NYSE: CLVT

$2.04 ▲ +0.10 (+5.15%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.25 Bn

P/E-9.09

P/S0.51

Div. Yield0.00

ROIC (Qtr)0.01

Total Debt (Qtr)4.28 Bn

Revenue Growth (1y) (Qtr)-1.38

Add ratio to table…

About

Clarivate Plc is a public limited company incorporated on January 7 2019 under the laws of Jersey Channel Islands with its principal offices located at 70 St Mary Axe London EC3A 8BE United Kingdom and its shares traded on the New York Stock Exchange under the ticker CLVT. The company describes itself as a leading global provider of transformative intelligence that supports the entire innovation lifecycle from cultivating curiosity to protecting critical intellectual property assets. Clarivate Plc offers intelligence solutions workflow solutions and tech enabled services to customers in the Academia & Government Intellectual Property and Life Sciences & Healthcare end markets aiming to fuel the world's greatest breakthroughs by harnessing human ingenuity. As of December 31 2025 the company employed more than 12 000 people across over 40 countries. The company's vision is to fuel the world's greatest breakthroughs by harnessing human ingenuity and its mission is to advance the success of people and organizations through transformative intelligence and trusted partnership.

Clarivate Plc generates revenue primarily through subscription arrangements recurring contracts and transactional offerings. Subscription based revenues are derived from annual contracts that license the right to use its products or provide maintenance services delivering stable and predictable cash flows. Recurring revenues come from patent and trademark renewal services that customers engage on a regular basis to maintain intellectual property rights benefiting from the company's high annual renewal rates which exceed ninety percent. Transactional revenues are earned for specific deliverables such as content sales consulting engagements and software implementation services typically quoted on a product data set or project basis. The subscription model provides a reliable revenue base while transactional offerings allow flexibility for specific projects.

The company operates through the following segments: Academia & Government (A&G) Intellectual Property (IP) and Life Sciences & Healthcare (LS&H). These segments are defined by the distinct products services and end markets they serve.

• Academia & Government (A&G) provides intelligence and workflow solutions for academic and government institutions including the Web of Science product family ProQuest content solutions and library software such as Alma Vega and Polaris to support the full research library lifecycle and research impact measurement using AI enabled tools. The segment also features the Academic AI platform which combines large language model technology with trusted scholarly content to deliver retrieval augmented generation and agentic AI capabilities for research and learning.

• Intellectual Property (IP) offers patent services patent intelligence brand IP solutions and IP management software including the Derwent World Patent Index Derwent Innovation CompuMark RiskMark IPfolio and FoundationIP to assist customers in protecting managing and commercializing patent and trademark assets. The segment provides patent maintenance administrative services trademark search and watch solutions and IP workflow automation tools such as IPfolio for portfolio management and FoundationIP for law firm services.

• Life Sciences & Healthcare (LS&H) delivers the Cortellis suite of products for research and development commercial and medtech needs including AI powered Regulatory Intelligence to help customers navigate drug development regulatory pathways market access and medical device commercialization. The segment also offers competitive intelligence clinical trial data and real world evidence analytics to support strategic decision making across the life sciences value chain.

Clarivate Plc believes it competes favorably on the depth breadth timeliness accuracy of its data and analysis the ease of use of its platforms and the value for price it offers. The company states that although it faces competition in specific markets and with respect to specific offerings it does not have a direct competitor across all of the markets it serves because of the breadth and depth of its portfolio. Clarivate Plc emphasizes that its competitive advantages stem from the richness of its curated data assets the integration of AI enabled technologies and its global reach across academia government intellectual property and life sciences sectors. The company has established an AI governance framework that sets principles for responsible development and deployment of generative AI across its product lines.

Clarivate Plc serves more than 45,000 customers worldwide spanning academic institutions and libraries research organizations corporations law firms government entities and companies in the pharmaceutical biotechnology and medical device sectors. Approximately 99 percent of the top 400 universities use its solutions more than 26,000 academic libraries benefit from its content over 40 patent offices rely on its data nine out of ten of the most valuable brands trust it with trademark needs over 1,600 corporations and law firms use its IP management software and it works with over 3,000 life sciences and healthcare customers. The company reports that its annual customer renewal rates exceed ninety percent reflecting strong satisfaction and loyalty across its diverse base. Its customer base is geographically diverse with significant presence in North America Europe Asia Pacific and other regions contributing to a balanced revenue stream.

Investment Thesis

▲ Bull case

Clarivate Plc is positioned to benefit significantly from the accelerated adoption of its AI-native platforms across high-margin segments, particularly through the recent launch of IPOne and Web of Science Research Intelligence, which are designed to embed proprietary data into enterprise AI workflows and institutional decision-making processes. These products are not incremental upgrades but represent a strategic shift toward AI-native, workflow-integrated solutions that increase switching costs and deepen customer reliance on Clarivate’s proprietary data assets. Management highlighted strong early traction, including over 400 institutions using academic AI solutions and 10,000+ researchers in Life Sciences engaging with AI tools, yet did not quantify the monetization pipeline or expansion velocity—suggesting the market may be underestimating the scalability of these offerings. The collaboration with Anthropic to integrate Cortellis regulatory intelligence into Anthropic Cloud Enterprise, combined with the Nexus Connect platform that aggregates content across LLMs, positions Clarivate as a critical data layer in the broader AI ecosystem, enabling it to capture value as enterprises increasingly seek trusted, domain-specific inputs to avoid hallucinations and bias in generative AI outputs. This ecosystem play could drive higher ACV expansion and improve retention rates beyond current guidance, especially as enterprises prioritize data provenance and compliance in AI deployments.
The ongoing portfolio rationalization, particularly the active pursuit of divesting the Life Sciences and Healthcare (LS&H) business, presents an underappreciated catalyst for margin expansion and strategic focus that is not fully reflected in current guidance. While management reaffirmed guidance assuming full-year ownership of LS&H, they explicitly noted that a divestiture would require a later revision to financial outlook—and highlighted that the process is ongoing with no guarantee of outcome, yet emphasized the objective is to maximize shareholder value by sharpening focus on higher-return businesses. LS&H currently carries the lowest subscription mix and highest transactional revenue exposure, making it a drag on overall recurring revenue predictability and margin profile. Its removal would instantly elevate the company-wide subscription mix (already at 88%-89%) toward the low nineties, reduce revenue volatility, and allow redeployment of capital and management attention toward Academia & Government and Intellectual Property—segments where AI innovation is yielding the strongest growth and highest adjusted EBITDA margins. The market appears to be pricing in the status quo, but a successful divestiture could trigger a multiple re-rating as Clarivate transitions into a purer-play, high-margin intelligence and workflow provider with superior cash conversion characteristics.
Clarivate’s deleveraging trajectory is more aggressive and sustainable than implied by current guidance, with free cash flow generation poised to accelerate beyond the $400 million midpoint due to underappreciated operating leverage from AI-driven internal efficiencies and the structural improvement in working capital dynamics. Management disclosed that they are deploying AI across go-to-market, technology, and corporate functions to automate workflows, reduce manual effort, and improve accuracy—specifically citing expectations that digital agents will reduce manual effort and create operating leverage. Yet, they refrained from quantifying these savings, noting only that they would “look to further dimension this probably later this year.” Combined with the $1.2 billion of cumulative free cash flow generated over the past three years (averaging over $100 million per quarter), and the favorable debt maturity profile with no near-term maturities, the company is well-positioned to retire secured notes ahead of the 2028 timeline outlined. If internal AI efficiencies deliver even a 100-basis-point improvement in adjusted EBITDA margin beyond the guided 200-basis-point expansion (via reduced SG&A and lower cost-to-serve), free cash flow could exceed $500 million annually, accelerating deleverage and enabling more aggressive share repurchases or debt reduction—factors not modeled into current valuations but capable of significantly boosting equity value over the next 18-24 months.
The Intellectual Property (IP) segment is showing early signs of a sustainable inflection point that the market is overlooking due to its focus on near-term transactional volatility and historical decline patterns. Management noted that renewal rates improved approximately 100 basis points in Q1, helping organic ACV trend to nearly flat—a clear improvement versus prior multi-year declines—and highlighted that the largest recurring revenue stream (patent renewals) was flat last year and is expected to return to growth in the second half of 2026, driven by improving patent stock growth as a leading indicator and enhanced sales execution. Crucially, they emphasized that IP is the only company with all three or four sub-offerings (IPMS, trademark, patent intelligence) and that the new management team has implemented strong focus on sales execution and AI innovation—citing Brand Image Search as an example of agentic AI expanding how professionals uncover insights. The market appears to be pricing IP as a stagnant or declining legacy business, but the combination of stabilizing renewal trends, AI-powered product differentiation, and renewed sales discipline suggests the segment may be entering a phase of low-single-digit organic growth with expanding margins—potentially contributing more to overall growth than currently anticipated, especially if AI agents like those in IPOne drive new use cases in corporate IP workflows and clearance processes.

Clarivate Plc is positioned to benefit significantly from the accelerated adoption of its AI-native platforms across high-margin segments, particularly through the recent launch of IPOne and Web of Science Research Intelligence, which are designed to embed proprietary data into enterprise AI workflows and institutional decision-making processes. These products are not incremental upgrades but represent a strategic shift toward AI-native, workflow-integrated solutions that increase switching costs and deepen customer reliance on Clarivate’s proprietary data assets. Management highlighted strong early traction, including over 400 institutions using academic AI solutions and 10,000+ researchers in Life Sciences engaging with AI tools, yet did not quantify the monetization pipeline or expansion velocity—suggesting the market may be underestimating the scalability of these offerings. The collaboration with Anthropic to integrate Cortellis regulatory intelligence into Anthropic Cloud Enterprise, combined with the Nexus Connect platform that aggregates content across LLMs, positions Clarivate as a critical data layer in the broader AI ecosystem, enabling it to capture value as enterprises increasingly seek trusted, domain-specific inputs to avoid hallucinations and bias in generative AI outputs. This ecosystem play could drive higher ACV expansion and improve retention rates beyond current guidance, especially as enterprises prioritize data provenance and compliance in AI deployments.
The ongoing portfolio rationalization, particularly the active pursuit of divesting the Life Sciences and Healthcare (LS&H) business, presents an underappreciated catalyst for margin expansion and strategic focus that is not fully reflected in current guidance. While management reaffirmed guidance assuming full-year ownership of LS&H, they explicitly noted that a divestiture would require a later revision to financial outlook—and highlighted that the process is ongoing with no guarantee of outcome, yet emphasized the objective is to maximize shareholder value by sharpening focus on higher-return businesses. LS&H currently carries the lowest subscription mix and highest transactional revenue exposure, making it a drag on overall recurring revenue predictability and margin profile. Its removal would instantly elevate the company-wide subscription mix (already at 88%-89%) toward the low nineties, reduce revenue volatility, and allow redeployment of capital and management attention toward Academia & Government and Intellectual Property—segments where AI innovation is yielding the strongest growth and highest adjusted EBITDA margins. The market appears to be pricing in the status quo, but a successful divestiture could trigger a multiple re-rating as Clarivate transitions into a purer-play, high-margin intelligence and workflow provider with superior cash conversion characteristics.
Clarivate’s deleveraging trajectory is more aggressive and sustainable than implied by current guidance, with free cash flow generation poised to accelerate beyond the $400 million midpoint due to underappreciated operating leverage from AI-driven internal efficiencies and the structural improvement in working capital dynamics. Management disclosed that they are deploying AI across go-to-market, technology, and corporate functions to automate workflows, reduce manual effort, and improve accuracy—specifically citing expectations that digital agents will reduce manual effort and create operating leverage. Yet, they refrained from quantifying these savings, noting only that they would “look to further dimension this probably later this year.” Combined with the $1.2 billion of cumulative free cash flow generated over the past three years (averaging over $100 million per quarter), and the favorable debt maturity profile with no near-term maturities, the company is well-positioned to retire secured notes ahead of the 2028 timeline outlined. If internal AI efficiencies deliver even a 100-basis-point improvement in adjusted EBITDA margin beyond the guided 200-basis-point expansion (via reduced SG&A and lower cost-to-serve), free cash flow could exceed $500 million annually, accelerating deleverage and enabling more aggressive share repurchases or debt reduction—factors not modeled into current valuations but capable of significantly boosting equity value over the next 18-24 months.
The Intellectual Property (IP) segment is showing early signs of a sustainable inflection point that the market is overlooking due to its focus on near-term transactional volatility and historical decline patterns. Management noted that renewal rates improved approximately 100 basis points in Q1, helping organic ACV trend to nearly flat—a clear improvement versus prior multi-year declines—and highlighted that the largest recurring revenue stream (patent renewals) was flat last year and is expected to return to growth in the second half of 2026, driven by improving patent stock growth as a leading indicator and enhanced sales execution. Crucially, they emphasized that IP is the only company with all three or four sub-offerings (IPMS, trademark, patent intelligence) and that the new management team has implemented strong focus on sales execution and AI innovation—citing Brand Image Search as an example of agentic AI expanding how professionals uncover insights. The market appears to be pricing IP as a stagnant or declining legacy business, but the combination of stabilizing renewal trends, AI-powered product differentiation, and renewed sales discipline suggests the segment may be entering a phase of low-single-digit organic growth with expanding margins—potentially contributing more to overall growth than currently anticipated, especially if AI agents like those in IPOne drive new use cases in corporate IP workflows and clearance processes.

▼ Bear case

Clarivate Plc’s organic growth remains fragile and overly dependent on subscription accretion that may not be sustainable without continued price increases or new customer wins, raising concerns about the quality of its 1.6% organic ACV growth and 1.7% subscription organic revenue growth in Q1. Management acknowledged that organic recurring revenue growth of 1.0% was driven by subscription strength partially offset by declines in re-occurring and transactional revenues, with the IP segment showing a 1.3% organic decline and Life Sciences only 0.8% growth—suggesting the core engines of growth are weak and reliant on pricing power rather than volume expansion. The company did not address churn or contraction rates in the Q&A, despite repeated focus on renewal rates improving by only 100 basis points—a marginal improvement that leaves the business still vulnerable to downgrades or non-renewals, especially in transactional-heavy segments like LS&H. Furthermore, the reliance on new customer wins (e.g., Spire University, top 20 pharma customer for DRG Fusion) as a growth driver introduces execution risk, as these wins are lumpy and not yet showing signs of becoming a predictable, scalable engine. If macroeconomic pressures lead to reduced research spending or tighter IP budgets in corporate and government sectors, the company’s ability to maintain even low-single-digit organic growth could be challenged, calling into question the durability of its subscription-led transition.
The artificial intelligence (AI) narrative, while prominently featured in management’s commentary, lacks tangible financial evidence of monetization or competitive differentiation, creating a significant risk that the market is overestimating the near-term impact of AI initiatives on revenue and margins. Although Clarivate highlighted product launches like IPOne, Web of Science Research Intelligence, and Nexus Connect, and cited internal AI efficiencies in go-to-market, technology, and corporate functions, they provided no concrete metrics on AI-driven revenue contribution, customer expansion rates, or cost savings realized to date—only qualitative statements such as “we are seeing great adoption” and “we have been recognized as an AI innovator.” The absence of quantified outcomes, particularly in the context of intense competition from large tech firms (e.g., Google Scholar, Microsoft Academic, specialized legal AI startups) and open-access alternatives, raises doubts about whether Clarivate’s proprietary data advantages can sustain premium pricing in an era where AI models are increasingly trained on scraped or publicly available data. Moreover, the internal AI efficiency initiatives—while framed as margin expanders—remain unmeasured and could fail to deliver scale if integration complexities, data silos, or change management challenges limit adoption, leaving the company to bear the cost of AI investments without commensurate returns.
Clarivate’s balance sheet remains burdened by high leverage and significant intangible assets, creating downside risk to earnings and valuation if free cash flow generation falters or if impairment triggers arise from overvalued goodwill and acquired intangibles. As of March 31, 2026, the company reported $4.3268 billion in total debt and $7.8637 billion in other intangible assets net, alongside $1.5666 billion in goodwill—meaning intangible assets and goodwill collectively represent over 85% of total assets. While management emphasized debt reduction progress (retiring $143 million in Q1) and outlined a plan to retire secured notes by 2028, the adjusted EBITDA of $241.2 million in Q1 implies an annualized run rate of ~$965 million, resulting in a net leverage ratio of approximately 4.5x based on current debt levels. Even if free cash flow reaches the guided $400 million annually, deleveraging to the target of 2.5x would take multiple years, leaving the company vulnerable to interest rate fluctuations or covenant pressures. More critically, the $135.4 million in quarterly amortization of acquired intangible assets (annualizing to ~$540 million) represents a substantial non-cash drag on GAAP earnings, and any slowdown in growth could prompt impairment reviews—especially if the LS&H divestiture process fails or if AI investments fail to generate expected returns—potentially triggering significant write-downs that would devastate reported earnings and investor confidence.
The Life Sciences and Healthcare (LS&H) segment’s ongoing divestiture process introduces material uncertainty and execution risk that could undermine near-term financial performance and distract management, despite being framed as a strategic positive. Although leadership stated they are “actively pursuing the sale” and that it aligns with concentrating capital on higher-return businesses, they also explicitly warned that guidance assumes full-year ownership and that a divestiture would require a later revision—highlighting that the outcome is not guaranteed and that updates will be provided only “as appropriate.” This ambiguity creates a material overhang: if the sale drags on or fails to close, the company remains saddled with a low-margin, transactional-heavy business that reported only 0.8% organic revenue growth in Q1 and continues to drag down the overall subscription mix. Conversely, if a sale is announced, it could trigger near-term disruption in customer relationships, sales force realignment, and potential revenue leakage during transition—especially given LS&H’s reliance on consulting and transactional services tied to commercialization workflows. Furthermore, the use of proceeds from any divestiture remains unspecified; if not directed toward debt reduction or share buybacks, the strategic rationale could be questioned. The market may be pricing in a clean, value-accretive divestiture, but the lack of clarity on timing, valuation, and use of proceeds presents a tangible risk to near-term execution and focus.

Clarivate Plc’s organic growth remains fragile and overly dependent on subscription accretion that may not be sustainable without continued price increases or new customer wins, raising concerns about the quality of its 1.6% organic ACV growth and 1.7% subscription organic revenue growth in Q1. Management acknowledged that organic recurring revenue growth of 1.0% was driven by subscription strength partially offset by declines in re-occurring and transactional revenues, with the IP segment showing a 1.3% organic decline and Life Sciences only 0.8% growth—suggesting the core engines of growth are weak and reliant on pricing power rather than volume expansion. The company did not address churn or contraction rates in the Q&A, despite repeated focus on renewal rates improving by only 100 basis points—a marginal improvement that leaves the business still vulnerable to downgrades or non-renewals, especially in transactional-heavy segments like LS&H. Furthermore, the reliance on new customer wins (e.g., Spire University, top 20 pharma customer for DRG Fusion) as a growth driver introduces execution risk, as these wins are lumpy and not yet showing signs of becoming a predictable, scalable engine. If macroeconomic pressures lead to reduced research spending or tighter IP budgets in corporate and government sectors, the company’s ability to maintain even low-single-digit organic growth could be challenged, calling into question the durability of its subscription-led transition.
The artificial intelligence (AI) narrative, while prominently featured in management’s commentary, lacks tangible financial evidence of monetization or competitive differentiation, creating a significant risk that the market is overestimating the near-term impact of AI initiatives on revenue and margins. Although Clarivate highlighted product launches like IPOne, Web of Science Research Intelligence, and Nexus Connect, and cited internal AI efficiencies in go-to-market, technology, and corporate functions, they provided no concrete metrics on AI-driven revenue contribution, customer expansion rates, or cost savings realized to date—only qualitative statements such as “we are seeing great adoption” and “we have been recognized as an AI innovator.” The absence of quantified outcomes, particularly in the context of intense competition from large tech firms (e.g., Google Scholar, Microsoft Academic, specialized legal AI startups) and open-access alternatives, raises doubts about whether Clarivate’s proprietary data advantages can sustain premium pricing in an era where AI models are increasingly trained on scraped or publicly available data. Moreover, the internal AI efficiency initiatives—while framed as margin expanders—remain unmeasured and could fail to deliver scale if integration complexities, data silos, or change management challenges limit adoption, leaving the company to bear the cost of AI investments without commensurate returns.
Clarivate’s balance sheet remains burdened by high leverage and significant intangible assets, creating downside risk to earnings and valuation if free cash flow generation falters or if impairment triggers arise from overvalued goodwill and acquired intangibles. As of March 31, 2026, the company reported $4.3268 billion in total debt and $7.8637 billion in other intangible assets net, alongside $1.5666 billion in goodwill—meaning intangible assets and goodwill collectively represent over 85% of total assets. While management emphasized debt reduction progress (retiring $143 million in Q1) and outlined a plan to retire secured notes by 2028, the adjusted EBITDA of $241.2 million in Q1 implies an annualized run rate of ~$965 million, resulting in a net leverage ratio of approximately 4.5x based on current debt levels. Even if free cash flow reaches the guided $400 million annually, deleveraging to the target of 2.5x would take multiple years, leaving the company vulnerable to interest rate fluctuations or covenant pressures. More critically, the $135.4 million in quarterly amortization of acquired intangible assets (annualizing to ~$540 million) represents a substantial non-cash drag on GAAP earnings, and any slowdown in growth could prompt impairment reviews—especially if the LS&H divestiture process fails or if AI investments fail to generate expected returns—potentially triggering significant write-downs that would devastate reported earnings and investor confidence.
The Life Sciences and Healthcare (LS&H) segment’s ongoing divestiture process introduces material uncertainty and execution risk that could undermine near-term financial performance and distract management, despite being framed as a strategic positive. Although leadership stated they are “actively pursuing the sale” and that it aligns with concentrating capital on higher-return businesses, they also explicitly warned that guidance assumes full-year ownership and that a divestiture would require a later revision—highlighting that the outcome is not guaranteed and that updates will be provided only “as appropriate.” This ambiguity creates a material overhang: if the sale drags on or fails to close, the company remains saddled with a low-margin, transactional-heavy business that reported only 0.8% organic revenue growth in Q1 and continues to drag down the overall subscription mix. Conversely, if a sale is announced, it could trigger near-term disruption in customer relationships, sales force realignment, and potential revenue leakage during transition—especially given LS&H’s reliance on consulting and transactional services tied to commercialization workflows. Furthermore, the use of proceeds from any divestiture remains unspecified; if not directed toward debt reduction or share buybacks, the strategic rationale could be questioned. The market may be pricing in a clean, value-accretive divestiture, but the lack of clarity on timing, valuation, and use of proceeds presents a tangible risk to near-term execution and focus.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Information Technology Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	IBM	International Business Machines Corp	193.88 Bn	8,812.83	2.81	61.99 Bn
2	ACN	Accenture plc	84.94 Bn	10.70	1.16	5.14 Bn
3	GDS	GDS Holdings Ltd	50.55 Bn	126.44	29.45	-
4	INFY	Infosys Ltd	44.05 Bn	0.29	0.05	-
5	GIB	Cgi Inc	41.25 Bn	0.32	3.47	2.65 Bn
6	FIS	Fidelity National Information Services, Inc.	20.63 Bn	134.81	1.80	16.99 Bn
7	CTSH	Cognizant Technology Solutions Corp	20.39 Bn	9.24	0.95	0.57 Bn
8	WIT	Wipro Ltd	18.65 Bn	12.56	1.80	1.88 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password